Opening Panel Discussion: Reflecting on Past Successes & Future Challenges Across the T-Cell Engager Landscape

  • Reflecting on the move away from first generation BiTE molecules to next-generation logic-gated and multi-specific T cell engagers
  • Exploring advancements in preclinical and clinical modelling of TCEs to allow for improvements in efficacy whilst minimizing system toxicity
  • Evaluating the potential for TCEs to serve as a scalable, off-the-shelf alternative to personalized CAR-T therapies